Wordt geladen...
Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway
Cisplatin has been the most accepted drug for the treatment of ovarian cancer for almost 40 years. Although the majority of patients with ovarian cancer respond to front-line platinum combination chemotherapy, many patients will develop cisplatin-resistance disease, which is extremely rapid and fata...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Public Library of Science
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4035252/ https://ncbi.nlm.nih.gov/pubmed/24865582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0097094 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|